Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations
Open Access
- 26 November 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (23) , 5965-5975
Abstract
Adoptive transfer of virus-specific T cells (VSTs) has been used for managing viral diseases in immunocompromised patients, including those undergoing hematopoietic stem cell transplantation and solid organ transplantation. Clinical trials targeting viruses such as cytomegalovirus, Epstein-Barr virus, adenovirus, and BK virus have demonstrated effective viral control without the toxicities associated with conventional antiviral therapies. This review explores the manufacturing, feasibility, safety, and efficacy of VSTs, complemented by 2 case studies illustrating their real-world application. We examine recent advancements in VST manufacturing that broaden their accessibility and applicability to a wider range of viral infections and immunocompromised populations. Key safety considerations, including cytokine release syndrome and graft-versus-host disease, are discussed. Lastly, we assess the expanding applications of VSTs against emerging viral targets, such as COVID-19, and address current barriers to their implementation beyond the research setting.Keywords
This publication has 104 references indexed in Scilit:
- Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal LeukoencephalopathyJAMA Neurology, 2024
- Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplantAmerican Journal of Transplantation, 2024
- On behalf of the SFGM‐TC: Real‐life use of third‐party virus‐specific T‐cell transfer in immunocompromised transplanted patientsHemaSphere, 2024
- Viral‐specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success storyPediatric Blood & Cancer, 2023
- Adoptive therapy with cytomegalovirus‐specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacyAmerican Journal of Hematology, 2022
- Failure of Viral-Specific T Cells Administered in Pre-transplant Settings in Children with Inborn Errors of ImmunityJournal of Clinical Immunology, 2021
- Adoptive Transfer of JC Virus‐Specific T Lymphocytes for the Treatment of Progressive Multifocal LeukoencephalopathyAnnals of Neurology, 2021
- Prophylactic antigen‐specific T‐cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplantClinical & Translational Immunology, 2021
- EBV‐directed viral‐specific T‐lymphocyte therapy for the treatment of EBV‐driven lymphoma in two patients with primary immunodeficiency and DNA repair defectsPediatric Blood & Cancer, 2019
- Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Be Efficiently Expanded from Granulocyte Colony-Stimulating Factor–Mobilized Hemopoietic Progenitor Cell Products Ex Vivo and Safely Transferred to Stem Cell Transplantation Recipients to Facilitate Immune ReconstitutionTransplantation and Cellular Therapy, 2013